Bioo Scientific Launches In Vivo siRNA Delivery Reagent

05-May-2009 - RNAi is a potentially powerful but challenging tool for therapeutics and validation studies. One of the primary challenges of achieving optimal in vivo RNAi is developing an effective in vivo siRNA delivery system. The research team at Bioo Scientific developed MaxSuppressor™ In Vivo RNA-LANCEr ...

Marinomed Granted European Patent for Antiviral Polymer

04-May-2009 - Marinomed Biotechnologie GmbH announced that it has been granted European Patent No. 0001842546, entitled ‘Antiviral polymer’ by the European Patent Office. The patent covers the use of a specific polymer for the prophylactic and therapeutic treatment of rhinovirus infections. Dr Andreas ...

Gifted guardians of life and the environment: Europe honours the inventors of the year

04-May-2009 - Health and the environment were the big winners when the European Commission and the European Patent Office presented the 2009 European Inventor of the Year awards. In the presence of the Head of the Czech Parliament Miloslav Vlcek and over 400 guests in Prague Castle, EPO President Alison ...

Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women

30-Apr-2009 - Wyeth Pharmaceuticals, a division of Wyeth, announced that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. The ...

Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

Phase 1 healthy volunteer study of IMX942 will provide human safety and pharmacodynamic data

30-Apr-2009 - Inimex Pharmaceuticals announced that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study of IMX942 being performed for Inimex in Montreal with the approval of ...

Medicago initiates work on Swine Flu strain

30-Apr-2009 - Medicago Inc. announced that it has received a genetic sequence of the new strain of influenza A (H1N1) that has recently been identified in USA and Mexico, and has commenced laboratory work with its VLP vaccine technology to produce material for testing. According to the World Health ...

UCB announces first results from Phase III brivaracetam studies in epilepsy

One study met its primary efficacy endpoint while the second study did not meet its primary efficacy endpoint

29-Apr-2009 - UCB announced top-line results from two Phase III clinical studies to assess the efficacy and safety of brivaracetam as adjunctive treatment of partial-onset seizures in adults with epilepsy. Results were also announced for a third well-controlled safety and tolerability study. Study N01253 ...

Bosentan (Tracleer) receives positive CHMP opinion for pediatric formulation

28-Apr-2009 - Actelion Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for the pediatric formulation of bosentan (Tracleer®) for the treatment of pulmonary arterial hypertension (PAH). The ...

Removab Approval: Proof-of-Concept for Technology Transfer in Germany

27-Apr-2009 - The European Commission has granted approval for the trifunctional anti-cancer antibody Removab®. It is the first approved therapeutic antibody originating from a German research institution that has been brought to market by its own spin-out together with a pharma partner. "This success story ...

Transgene presents additional Phase I data for TG4040 in Hepatitis C chronically infected patients

27-Apr-2009 - Transgene S.A. announced additional interim results from its ongoing Phase I clinical study of its therapeutic vaccine TG4040 (MVA-HCV) conducted in treatment-naive patients chronically infected with the Hepatitis C Virus (HCV), and its decision to initiate a Phase II trial, planned for the ...